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Hyperammonemia in a Patient with Late-Onset Ornithine 
Carbamoyltransferase Deficiency
Ornithine carbamoyltransferase (OTC) deficiency is a urea cycle disorder that causes the 
accumulation of ammonia, which can lead to encephalopathy. Adults presenting with 
hyperammonemia who are subsequently diagnosed with urea cycle disorders are rare. 
Herein, we report a case of a late-onset OTC deficient patient who was successfully treated 
with arginine, benzoate and hemodialysis. A 59-yr-old man was admitted to our hospital 
with progressive lethargy and confusion. Although hyperammonemia was suspected as the 
cause of the patient’s mental changes, there was no evidence of chronic liver disease.  
A plasma amino acid and urine organic acid analysis revealed OTC deficiency. Despite the 
administration of a lactulose enema, the patient’s serum ammonia level increased and he 
remained confused, leading us to initiate acute hemodialysis. After treatment with 
arginine, sodium benzoate and hemodialysis, the patient’s serum ammonia level stabilized 
and his mental status returned to normal. 
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CASE REPORT
Nephrology
INTRODUCTION
The amino acid products of endogenous and exogenous pro-
tein digestion are degraded by hepatic transamination and oxi-
dative deamination to produce ammonia. Ammonia is then con-
verted to urea via the five enzymes of the urea cycle (carbamoyl 
phosphate synthetase, ornithine carbamoyltransferase (OTC), 
argininosuccinic acid synthetase, argininosuccinase, and argi-
nase), and excreted by the kidneys (1). Any disruption to this 
nitrogen excretion pathway has the potential to cause hyper-
ammonemia and clinical encephalopathy.
  The most common genetic disorder of the urea cycle is a de-
ficiency in OTC (2). OTC deficiency is heterogeneous in its pre-
sentation (3), but its symptoms are induced by hyperammone-
mia caused by the accumulation of precursors of urea, primari-
ly ammonia and glutamine (1). The presentation of severe hy-
perammonemia caused by OTC deficiency varies with the age 
of the patient. In infants, hyperammonemia is associated with 
lethargy, poor sucking response, vomiting, hypotonia, and sei-
zures (4). In adults, although disruption of the urea cycle is usu-
ally a result of liver disease (cirrhosis) or chemotherapy rather 
than a genetic defect, partial or late-onset OTC deficiency can 
result from residual enzyme activity associated with peripheral 
mutations in the OTC gene. Its phenotypes are diverse, ranging 
from severe to apparently asymptomatic (5). 
  Here we describe a case of late-onset OTC deficiency present-
ing as severe acute hyperammonemia with coma, and success-
ful treatment with arginine, benzoate and hemodialysis.
  
CASE DESCRIPTION
A 59-yr-old man was admitted to our hospital because he had 
exhibited progressive lethargy and confusion since the early 
morning. He had often complained of fatigue over the previous 
3 months. Three days prior to presentation, he had eaten a large 
amount of dog meat at a party, become nauseated, and vomit-
ed. The next day, he had eaten chicken and freshwater snails, 
had again become nauseated, and developed severe vomiting. 
On the day of admission, he failed to arise at his normal time 
and exhibited inappropriate behavior and drowsiness.   
  During his childhood, the patient had suffered recurrent ab-
dominal pain and periodic episodes of convulsions, but he had 
not experienced any seizures in adulthood. On examination, the 
patient was in a semi-coma; his Glasgow Coma Scale score was 
10/15, and he was disoriented in time, place, and person. His 
vital signs were stable, with a blood pressure of 150/80 mmHg, 
pulse rate of 84/min, respiratory rate of 24/min, and body tem-
perature of 36°C. Laboratory investigations showed that he had 
hyperammonemia (143.8 mM), elevated liver enzymes (alanine 
aminotransferase, 179 U/L; aspartate aminotransferase, 91 U/L), 
a total bilirubin level of 1.91 mg/dL, and a blood glucose level of 
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were 17.7 mg/dL and 1.01 mg/dL, respectively. Blood analysis 
revealed mild leukocytosis (10.41 × 10
3 leukocytes/µL) and               
a normal hemoglobin level, platelet count, and clotting profile. 
Serum electrolyte analysis showed mild hypernatremia (149 mEq 
sodium/L), but serum potassium and chloride levels were with-
in normal range. Results of a toxicology screen were normal.
  Further investigations revealed no evidence of gastrointesti-
nal bleeding, and computed tomography (CT) and diffusion-
weighted magnetic resonance imaging revealed no brain lesions. 
Abdominal CT imaging did not show any abnormality. The cere-
brospinal fluid was normal upon examination. 
  Although hyperammonemia was suspected as the cause of 
the patient’s mental changes, there was no evidence of chronic 
liver disease. Despite the administration of a lactulose enema, 
the patient’s serum ammonia level increased to 370 mM and he 
remained confused, leading us to initiate acute hemodialysis. 
During the procedure, the patient had a generalized tonic-clonic 
seizure, for which 1 mg of lorazepam was administered intrave-
nously. The seizure subsided, but the patient continued to move 
convulsively, leading to several additional injections of intrave-
nous lorazepam. A diagnosis of nonconvulsive status epilepti-
cus was made, and the antiepileptic drug levetiracetam was ad-
ministered. 
  After the initial session of hemodialysis, the patient’s serum 
ammonia level had decreased to 170 mM, but it soon rose to 
228 mM. Plasma and urine amino acid analysis and urine organ-
ic acid quantitation were performed. Under suspicion of a urea 
cycle disorder, arginine (3 g) and sodium benzoate (3 g) were 
administered via nasogastric tube every 4-6 hr. Dextrose solution 
(10%) was supplied intravenously, and a protein-free formula 
was supplied via a feeding tube. 
  By the morning of the next day, the patient’s serum ammonia 
level had decreased to 36 mM. However, because it rose to 107 
mM by the afternoon, and the patient was still semi-comatose, 
hemodialysis was performed one more time. At that time, an 
electroencephalogram did not show any signs of epileptic dis-
charge. 
  After the second hemodialysis session, the patient’s serum 
ammonia level stabilized at less than 30 mM. A plasma amino 
acids analysis revealed elevated ornithine (196 µM; normal 19-
81 µM), decreased citrulline (3 μM; normal 19-62 µM), and ele-
vated glutamine and lysine. Urine organic acids analysis revealed 
highly elevated urinary orotic acid (603.5 mg/mg creatinine) and 
a mild urinary uracil peak. No liver biopsy or genetic analysis 
was performed.
  The accumulated evidence led to a diagnosis of late-onset 
ornithine carbamoyltransferase deficiency. After 5 days, the pa-
tient’s mental status returned to normal. He continued to receive 
sodium benzoate (3 g) and arginine (3 g) three times daily. The 
protein-free formula, which was administered continuously, was 
gradually changed to increase the dietary protein without a sig-
nificant rise in serum ammonia levels (Fig. 1). The patient was 
discharged home after 2 weeks with instructions to continue the 
medication and formula. His family received special counsel-
ing on diet and emergency management before his discharge. 
DISCUSSION 
The ornithine carbamoyltransferase (OTC) gene is encoded on 
the X chromosome and is expressed in the mitochondrial ma-
trix of the small intestine and liver, where it catalyzes the syn-
thesis of citrulline from carbamoyl phosphate and ornithine (1). 
OTC deficiency has an estimated incidence of 1 in 14,000 and is 
the only urea cycle disorder that is X-linked (1). Recent research 
on the biochemical and molecular bases of OTC deficiency by 
Tuchman et al. (6) revealed a wide spectrum of genetic defects 
resulting in different phenotypes. Mutations predicted to abol-
ish all enzyme activity were found in the neonatal onset group, 
while mutations causing partial or varying enzyme deficiency 
were found in the late onset group (7). Patients who were asymp-
Fig. 1. Effect of arginine, sodium benzoate and hemodialysis in a late-onset ornithine transcarbamylase deficiency.
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tomatic until much later in life were almost always heterozygotes 
and symptom onset coincided with a precipitating factor such 
as infection, trauma, sodium valproate, surgery, childbirth, phys-
iological stress or, as in our patient, excess protein intake (8, 9). 
  A diagnosis of OTC deficiency is confirmed when plasma 
amino acid analysis reveals elevated glutamine and alanine 
levels and a decreased citrulline level, and orotic acid and uri-
dine are found in the urine (1). The diagnosis can be followed 
up by liver biopsy to measure OTC enzyme activity and muta-
tion analysis. The measurement of urinary orotidine excretion 
after allopurinol administration can be used as a simple and   
reliable test to detect carriers (10). DNA analysis of the affected 
gene is the most reliable method for detecting the carrier state 
of females and for making a prenatal diagnosis in a family with 
a positive family history (11). In our patient, the amino acid anal-
yses of his plasma and urine were consistent with OTC deficien-
cy, allowing us to explain the etiology of his hyperammonemia 
and coma. Although a discussion of his family medical history 
eventually revealed that four uncles of the patient had died of 
unknown causes after eating a large amount of meat (Fig. 2), no 
genetic analyses were performed.
  The therapeutic principles for management of OTC deficien-
cy include minimizing endogenous ammonia production, pro-
tein catabolism, and nitrogen intake; administration of urea cy-
cle substrates that are lacking as a consequence of the enzymatic 
defect; and administration of compounds that facilitate the re-
moval of ammonia through alternative pathways (1). By activat-
ing N-acetylglutamate synthetase, arginine activates the urea 
cycle (12). Oral supplementation or intravenous infusion is rec-
ommended. Benzoate and phenylacetate, by conjugating with 
glycine and glutamine, respectively, remove excess nitrogen via 
alternative pathways (8). There are no definite guidelines as to 
when to initiate dialysis in a patient with hyperammonemia. 
However, if the blood ammonia level is more than three to four 
times the upper limit of normal or is increasing quickly, and/or 
if the patient is encephalopathic, high-efficiency intermittent 
hemodialysis should be considered (13). For the encephalo-
pathic patient with hyperammonemia, rapid initiation of dialy-
sis is critical to minimize the brain damage resulting from con-
tinued exposure to elevated blood ammonia. The rapid removal 
of ammonia by hemodialysis is not associated with disequilib-
rium syndrome because ammonia is a gas and not osmotically 
active (14). After a normal blood ammonia level is achieved,  
dialysis can be stopped, and the patient can be maintained on 
urea cycle medications. 
  This case illustrates the under-recognized fact that late-onset 
OTC deficiency can occur at any age; our patient was 54 yr old. 
His late-onset OTC deficiency was successfully treated with he-
modialysis and arginine and benzoate administration. Unex-
plained neurological symptoms in a patient with no history of 
liver disease should raise the suspicion of a urea cycle disorder, 
as many cases will respond to treatment with a favorable out-
come.
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